<DOC>
	<DOCNO>NCT01383330</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics Daewon DW-ES ( A ) 625mg/5ml , Daewon DW-ES ( B ) 625mg/5ml Megace 800mg/20ml healthy male volunteer feed condition .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Pharmacokinetics Daewon DW-ES ( A ) 625mg/5ml , Daewon DW-ES ( B ) 625mg/5ml Megace 800mg/20ml Healthy Male Volunteers Under Fed Condition</brief_title>
	<detailed_description />
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<criteria>Adult male age 20 55 year screen . No significant congenital/chronic disease . No symptoms physical examination . Appropriate subject determine past medical history , laboratory test , serology urinalysis . Be able understand objective , method study , characteristic investigational drug , comply requirement study . Subject must provide write informed consent prior study participation . History presence liver , kidney , nervous system disease , respiratory disorder , endocrinological disorder , hematooncologic , cardiovascular psychiatric cognitive disorder . History gastrointestinal disorder ( bleed , ulceration , hemorrhoid , pile ) disorder absorption , distribution , metabolism , excretion . History known hypersensitivity drug include valsartan pitavastatin .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>megesterol</keyword>
</DOC>